Disease · MONDO_0018874

acute myeloid leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute myeloid leukemia. Diseases, record MONDO_0018874. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018874

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute myeloid leukemia; Open Targets
Open Targets ID: MONDO_0018874; Open Targets
Other names: AML, AML - acute myeloid leukaemia, AML - acute myeloid leukemia, ANLL, acute Nonlymphocytic leukaemia, acute Nonlymphocytic leukemia, acute granulocytic leukaemia, acute granulocytic leukemia, acute myeloblastic leukemia, acute myelocytic leukaemia, acute myelocytic leukemia, acute myelogenous leukemia, acute myelogenous leukemias, acute myeloid leukaemia (AML), acute myeloid leukemia (AML), acute myeloid leukemia, somatic, hematopoeitic - acute Myleogenous leukaemia (AML), hematopoeitic - acute Myleogenous leukemia (AML), leukemia, acute myeloid, autosomal dominant, somatic mutation, leukemia, acute myeloid, reduced survival in, somatic, leukemia, acute myeloid, somatic, leukemia, acute myeloid, susceptibility to, autosomal dominant, somatic mutation, leukemia, myelocytic, acute, myeloid leukemia, acute, myeloid leukemia, acute, M4/M4Eo subtype, somatic; Open Targets
Disease Ontology: DOID:9119; Disease Ontology
MeSH: D015470; MeSH
NCI Thesaurus: C3171; NCI Thesaurus
Orphanet: ORPHA:519; Orphanet
Highest stage of its drugs: Approval, for 19 of its 587 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs587

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYTARABINE	CHEMBL803	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs, FDA and PMDA	662	659	636	Drugs and targets
AZACITIDINE	CHEMBL1489	Small molecule	Approval	EMA Human Drugs	448	441	419	Drugs and targets
DAUNORUBICIN	CHEMBL178	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs and FDA	172	170	148	Drugs and targets
GEMTUZUMAB OZOGAMICIN	CHEMBL1201506	Antibody drug conjugate	Approval	ClinicalTrials.gov and EMA Human Drugs	98	96	95	Drugs and targets
GILTERITINIB	CHEMBL3301622	Small molecule	Approval	ClinicalTrials.gov and EMA Human Drugs	58	57	57	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Approval	EMA Human Drugs	46	45	45	Drugs and targets
MIDOSTAURIN	CHEMBL608533	Small molecule	Approval	EMA Human Drugs and FDA	43	41	41	Drugs and targets
DAUNORUBICIN HYDROCHLORIDE	CHEMBL1563	Small molecule	Approval	PMDA	37	36	36	Drugs and targets
IVOSIDENIB	CHEMBL3989958	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs, FDA and PMDA	34	29	29	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Approval	FDA	23	22	19	Drugs and targets

1 to 10 of 587

See all 587 drugs

Targets470

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FLT3	Receptor-type tyrosine-protein kinase FLT3	25	Tyrosine-protein kinase receptor FLT3 binding agent; Tyrosine-protein kinase receptor FLT3 inhibitor	Approval	https://conductscience.org/library/genes/2322	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	20	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	18	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
KDR	Vascular endothelial growth factor receptor	17	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
ABL1	Bcr/Abl fusion protein	15	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 3	https://conductscience.org/library/genes/25	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	14	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	14	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	14	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Approval	https://conductscience.org/library/genes/7153	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	13	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5156	Drugs and targets
BCR	Bcr/Abl fusion protein	10	Bcr/Abl fusion protein inhibitor	Phase 3	https://conductscience.org/library/genes/613	Drugs and targets

1 to 10 of 470

See all 470 targets

Trials2,158

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 53 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	1,645	2020-07-07	Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma	ASPARAGINASE, BORTEZOMIB, CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00372593	Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	1,070	2015-01-13	Leukemia	GEMTUZUMAB OZOGAMICIN	Its record names the disease	ClinicalTrials.gov
NCT02348489	SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction	Phase 3	815	2021-01-14	Leukemia, Myeloid, Acute	GUADECITABINE	Its record names the disease	ClinicalTrials.gov
NCT01802333	Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia	Phase 3	754	2018-12-19	Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia	CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, IDARUBICIN, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03416179	A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia	Phase 3	730	2021-06-25	Leukemia, Myeloid, Acute	AZACITIDINE, CYTARABINE, DAUNORUBICIN, GLASDEGIB	Its record names the disease	ClinicalTrials.gov
NCT02085408	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	727	2023-03-09	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia	CLOFARABINE, CYTARABINE, DAUNORUBICIN, DECITABINE	Its record names the disease	ClinicalTrials.gov
NCT00651261	Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	717	2017-02-06	Leukemia	MIDOSTAURIN	Its record names the disease	ClinicalTrials.gov
NCT01191801	Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML	Phase 3	711	2017-05-09	Acute Myeloid Leukemia	CYTARABINE, VOSAROXIN	Its record names the disease	ClinicalTrials.gov
NCT00049517	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia	Phase 3	657	2013-02-12	Leukemia	BUSULFAN, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, FILGRASTIM, GEMTUZUMAB OZOGAMICIN, SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT00085709	S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML	Phase 3	637	2012-08-27	Leukemia	CYTARABINE, DAUNORUBICIN, GEMTUZUMAB OZOGAMICIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 2,158

See all 2,158 trials

Comparisons in its trials448

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SGI-110 (Guadecitabine) vs Treatment Choice: Number of Participants With Composite CR (CRc)	93 of 408	91 of 407	815	NCT02348489	Trial comparisons
SGI-110 (Guadecitabine) vs Treatment Choice: Number of Participants With a Complete Response (CR)	79 of 408	71 of 407	815	NCT02348489	Trial comparisons
SGI-110 (Guadecitabine) vs Treatment Choice: deaths from any cause	341 of 408	344 of 407	815	NCT02348489	Trial comparisons
SGI-110 (Guadecitabine) vs Treatment Choice: serious adverse events	327 of 401	297 of 392	793	NCT02348489	Trial comparisons
Induction and Consolidation Chemotherapy Plus Midostaurin vs Induction and Consolidation Chemotherapy Plus Placebo: serious adverse events	157 of 355	154 of 354	709	NCT00651261	Trial comparisons
Group A (Vosaroxin/Cytarabine) vs Group B (Placebo/Cytarabine): deaths from any cause	273 of 355	288 of 350	705	NCT01191801	Trial comparisons
Group A (Vosaroxin/Cytarabine) vs Group B (Placebo/Cytarabine): serious adverse events	197 of 355	125 of 350	705	NCT01191801	Trial comparisons
Standard Daunorubicin (Induction Therapy) vs High Dose Daunorubicin (Induction Therapy): serious adverse events	328 of 328	325 of 325	653	NCT00049517	Trial comparisons
Ara-C+Daunomycin vs Ara-C+Daunomycin+Mylotarg: Complete Remission	203 of 296	207 of 300	596	NCT00085709	Trial comparisons
Quizartinib vs Placebo: Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia	54 of 268	51 of 271	539	NCT02668653	Trial comparisons

1 to 10 of 448

See all 448 comparisons in its trials

Papers from its trials1,034

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40809193	RESULT	1	PubMed
40238563	RESULT	1	PubMed
39919267	RESULT	1	PubMed
39705540	RESULT	1	PubMed
39457618	RESULT	1	PubMed
39292927	RESULT	1	PubMed
39133921	RESULT	3	PubMed
38715059	RESULT	1	PubMed
38324741	RESULT	2	PubMed
37838437	RESULT	1	PubMed

1 to 10 of 1,034

See all 1,034 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018874

GET https://conductscience.org/api/diseases/v1/MONDO_0018874/drugs?page=2

API reference For AI assistants